Overview

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Status:
Completed
Trial end date:
2013-02-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right ventricle (RV) to left ventricle (LV) diameter within 48 =/- 6 hours in participants with massive or submassive PE.
Phase:
Phase 3
Details
Lead Sponsor:
Boston Scientific Corporation
EKOS Corporation
Collaborator:
EKOS Corporation
Treatments:
Plasminogen
Tissue Plasminogen Activator